Contraception
Volume 80, Issue 1 , Pages 84-89 , July 2009

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system

Received 18 June 2008 ,Revised 8 January 2009 ,Accepted 8 January 2009.

References 

  1. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90
  2. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78:716–721
  3. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65:129–132
  4. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception. 2002;65:325–328
  5. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004;291:1456–1463
  6. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG. 2002;109:136–144
  7. Hampton NRE, Rees MCP, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005;20:2653–2660
  8. Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993–1998
  9. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789–793
  10. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003;91:526–533
  11. Bahamondes L, Ribeiro-Huguet P, de Andrade KC, Leon-Martins O, Petta CA. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand. 2003;82:580–582
  12. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: WHO; 2004;
  13. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDs. Contraception. 1991;44:473–480
  14. Faúndes A, Alvarez F, Díaz J. A Latin American experience with levonorgestrel IUD. Ann Med. 1993;25:149–153
  15. Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo MM, Arce XE. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception. 2000;62:59–61
  16. Rodriguez G, Faundes A, Atkinson L. An approach to the analysis of menstrual patterns in the clinical evaluation of contraceptives. Stud Fam Plann. 1976;7:42–51
  17. Belsey EM, Machin D, D'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 1986;34:253–260
  18. Theron HB, Coetzee C, Sutherland FCW, Wiesner JL, Swart KJ. Selective and sensitive liquid chromatography–tandem mass spectrometry method for the determination of levonorgestrel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:331–336
  19. Nilsson CG, Lahteenmaki P, Robertson DN, Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intra-uterine devices. Acta Endocrinol (Copenh). 1980;93:380–384
  20. Nilsson CG, Luukkainen T, Lähteenmäki P. Determination of plasma concentrations of d-norgestrel during a one year follow-up in women with a d-norgestrel-releasing IUD. Contraception. 1978;17:569–573
  21. Nilsson CG, Lähteenmäki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception. 1980;21:225–233
  22. Jia MC, Zhou LY, Dong L, Xiao B. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept. 1992;8:33–40
  23. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984;41:52–55
  24. Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med. 1982;306:404–406
  25. Díaz J, Díaz MM, Pastene L, Araki R, Faúndes A. Randomized clinical study of the T-Cu 380A and the Lippes loop C, in Campinas, Brazil. Contraception. 1982;26:221–228

PII: S0010-7824(09)00005-5

doi: 10.1016/j.contraception.2009.01.004

Contraception
Volume 80, Issue 1 , Pages 84-89 , July 2009

Article Tools

* Image Usage & Resolution